Ensayo Prospectivo de Gastroplastía Endoscópica en Manga (ESG) para la Obesidad (EGO-Trial)
Estudio Prospectivo de Gastroplastia Endoscópica en Manga (ESG) para la Obesidad
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Armelle TAKEDA
- Número de teléfono: 0033 390 413608
- Correo electrónico: armelle.takeda@ihu-strasbourg.eu
Copia de seguridad de contactos de estudio
- Nombre: Clinical Research Team
- Correo electrónico: rc-ihu@ihu-strasbourg.eu
Ubicaciones de estudio
-
-
-
Aix-en-Provence, Francia
- Reclutamiento
- Hôpital Privé de Provence
-
Contacto:
- Hugues SEBBAG
- Número de teléfono: 0033 4 42 21 12 11
- Correo electrónico: hsebbag.ppr@hotmail.fr
-
Besançon, Francia
- Aún no reclutando
- Polyclinique de Franche-Comté
-
Contacto:
- Henry-Alexis MERCOLI
- Número de teléfono: 0033 3 81 41 81 41
- Correo electrónico: docteur.mercoli@gmail.com
-
Lille, Francia
- Aún no reclutando
- Hôpital HURIEZ
-
Contacto:
- Robert CAIAZZO
- Número de teléfono: 0033 3 20 44 42 73
- Correo electrónico: robert.caiazzo@univ-lille2.fr
-
Lyon, Francia
- Reclutamiento
- Clinique de la Sauvegarde
-
Contacto:
- Marie-Cécile BLANCHET
- Número de teléfono: +33 4 37 49 70 10
- Correo electrónico: blanchet@chirurgien-digestif.com
-
Lyon, Francia
- Reclutamiento
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
Contacto:
- Maud ROBERT
- Número de teléfono: 0033 4 72 11 62 61
- Correo electrónico: Maud.robert@chu-lyon.fr
-
Montpellier, Francia
- Aún no reclutando
- Clinique Clémentville
-
Contacto:
- Marta SILVESTRI
- Número de teléfono: 0033 4 67 06 70 00
- Correo electrónico: docteur.m.silvestri@gmail.com
-
Saint-Etienne, Francia
- Aún no reclutando
- Centre Mutualiste de l'Obésité
-
Contacto:
- Pierre BLANC
- Número de teléfono: 0033 4 77 81 82 88
- Correo electrónico: PBLANC@mutualite-loire.com
-
Saint-Grégoire, Francia
- Aún no reclutando
- CHP Saint-Grégoire
-
Contacto:
- Adrien STERKERS
- Número de teléfono: +33 2 99 23 93 10
- Correo electrónico: asterkers@vivalto-sante.com
-
Strasbourg, Francia
- Reclutamiento
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
Contacto:
- Silvana PERRETTA
- Número de teléfono: 0033 3 69 55 05 31
- Correo electrónico: perretta@unistra.fr
-
Sète, Francia
- Reclutamiento
- Polyclinique Sainte Thérèse
-
Contacto:
- Thibaut COSTE
- Número de teléfono: 0033 4 67 18 88 20
- Correo electrónico: thibautcoste@gmail.com
-
Échirolles, Francia
- Aún no reclutando
- Clnique des Cèdres
-
Contacto:
- Fabien STENARD
- Número de teléfono: 0033 4 56 58 14 90
- Correo electrónico: fabien.stenard@cliniquedescedres.com
-
-
-
-
-
Baie-Mahault, Guadalupe
- Aún no reclutando
- Clinique les Eaux Claires
-
Contacto:
- Venetia AVENDANO
- Número de teléfono: 0033 5 90 25 95 65
- Correo electrónico: zulemacu@yahoo.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adult patients with obesity scheduled for endoscopic gastroplasty
Descripción
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Todos los pacientes adultos con obesidad programados para gastroplastia endoscópica (ESG)
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total Body Weight Loss
Periodo de tiempo: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Excess weight loss
Periodo de tiempo: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
Periodo de tiempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
Periodo de tiempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
Periodo de tiempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
Periodo de tiempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
Periodo de tiempo: From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 25-004
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .